Peptilogics' lead compound PLG0206 received Qualified Infectious Disease Product designation by the FDA for prosthetic joint infection treatment.
Here are three things to know:
1. Peptilogics is a development stage biotechnology company developing antibiotics with a novel mechanism of action derived from their engineered cationic antibiotic peptide platform for the treatment of multidrug-resistant infections.
2. QIDP designation incentivizes the development of new antibiotics by including an additional five years of market exclusivity and eligibility for Priority Review and Fast Track designation.
3. According to Peptilogics CEO Sanjay Kakkar, MD, by 2020 more than 65,000 patients with prosthetic joint implants will develop PJIs per year, resulting in over $1.6 billion in annual inpatient costs.
More articles on orthopedics:
Continental Who's Who recognizes Dr. Kenneth Kaminski: 3 things to know
Orthopedic surgeon to know: Dr. Catherine Robertson of UC San Diego Health